KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Total Debt (2016 - 2025)

Merck (MRK) has disclosed Total Debt for 17 consecutive years, with $49.3 billion as the latest value for Q4 2025.

  • Quarterly Total Debt rose 32.95% to $49.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.3 billion through Dec 2025, up 32.95% year-over-year, with the annual reading at $49.3 billion for FY2025, 32.95% up from the prior year.
  • Total Debt for Q4 2025 was $49.3 billion at Merck, up from $41.4 billion in the prior quarter.
  • The five-year high for Total Debt was $49.3 billion in Q4 2025, with the low at $26.4 billion in Q3 2021.
  • Average Total Debt over 5 years is $34.4 billion, with a median of $34.5 billion recorded in 2024.
  • The sharpest move saw Total Debt fell 14.1% in 2021, then skyrocketed 32.95% in 2025.
  • Over 5 years, Total Debt stood at $33.1 billion in 2021, then fell by 7.28% to $30.7 billion in 2022, then increased by 14.22% to $35.1 billion in 2023, then grew by 5.87% to $37.1 billion in 2024, then surged by 32.95% to $49.3 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $49.3 billion, $41.4 billion, and $35.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.